DK0771566T3 - Stabilisering af kolloidale systemer ved dannelsen af ioniske lipidpolysaccharidkomplekser - Google Patents

Stabilisering af kolloidale systemer ved dannelsen af ioniske lipidpolysaccharidkomplekser

Info

Publication number
DK0771566T3
DK0771566T3 DK96914215T DK96914215T DK0771566T3 DK 0771566 T3 DK0771566 T3 DK 0771566T3 DK 96914215 T DK96914215 T DK 96914215T DK 96914215 T DK96914215 T DK 96914215T DK 0771566 T3 DK0771566 T3 DK 0771566T3
Authority
DK
Denmark
Prior art keywords
formation
colloidal systems
stabilization
systems
useful
Prior art date
Application number
DK96914215T
Other languages
English (en)
Inventor
Fernandez Maria Jose Un Alonso
Salve Pilar Universidade Calvo
Lopez Carmen Universid Remunan
Jato Jose Luis Universida Vila
Original Assignee
Advancell Advanced In Vitro Ce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advancell Advanced In Vitro Ce filed Critical Advancell Advanced In Vitro Ce
Application granted granted Critical
Publication of DK0771566T3 publication Critical patent/DK0771566T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK96914215T 1995-05-26 1996-05-24 Stabilisering af kolloidale systemer ved dannelsen af ioniske lipidpolysaccharidkomplekser DK0771566T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09501035A ES2093562B1 (es) 1995-05-26 1995-05-26 Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.

Publications (1)

Publication Number Publication Date
DK0771566T3 true DK0771566T3 (da) 2006-10-23

Family

ID=8290513

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96914215T DK0771566T3 (da) 1995-05-26 1996-05-24 Stabilisering af kolloidale systemer ved dannelsen af ioniske lipidpolysaccharidkomplekser

Country Status (9)

Country Link
US (1) US5843509A (da)
EP (1) EP0771566B1 (da)
AT (1) ATE330636T1 (da)
CA (1) CA2195881C (da)
DE (1) DE69634927T2 (da)
DK (1) DK0771566T3 (da)
ES (1) ES2093562B1 (da)
PT (1) PT771566E (da)
WO (1) WO1996037232A1 (da)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US6416778B1 (en) 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
FR2760641B1 (fr) * 1997-03-13 2000-08-18 Oreal Emulsion huile-dans-eau stable, son procede de fabrication et son utilisation dans les domaines cosmetique et dermatologique
DE19733625A1 (de) * 1997-07-28 1999-02-04 Lancaster Group Gmbh Dekorative kosmetische O/W-Emulsion
KR19990058599A (ko) * 1997-12-30 1999-07-15 손경식 이중 캡슐을 함유하는 화장료 조성물
DE19826503A1 (de) * 1998-06-13 1999-12-16 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen mit einem Gehalt an Chitosan und Phospholipiden
AU1275401A (en) * 1999-10-29 2001-05-14 Hunza Di Maria Carmela Marazzita S.A.S. Fibrous-liponutritional complexes and compositions containing them
FR2801811B1 (fr) * 1999-12-06 2002-05-03 Gerard Habar Procede de fabrication de microcapsules portant des charges cationiques
AU2001246459A1 (en) * 2000-02-23 2001-09-03 Henkel Kommanditgesellschaft Auf Aktien Microcapsules and/or nanocapsules
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
US6455073B1 (en) 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
US6689760B1 (en) 2000-07-10 2004-02-10 Enzrel Inc. Anti-mycobacterial compositions
AU2001296480A1 (en) 2000-10-02 2002-04-15 Kimberly-Clark Worldwide, Inc. Recording medium with nanoparticles and methods of making the same
US20030133972A1 (en) * 2000-10-11 2003-07-17 Targesome, Inc. Targeted multivalent macromolecules
US20030129223A1 (en) * 2000-10-11 2003-07-10 Targesome, Inc. Targeted multivalent macromolecules
WO2002072011A2 (en) * 2001-03-08 2002-09-19 Targesome, Inc. Stabilized therapeutic and imaging agents
US6673263B2 (en) 2001-07-26 2004-01-06 Ppg Industries Ohio, Inc. Compositions incorporating chitosan for paint detackification
US20040000329A1 (en) * 2001-07-26 2004-01-01 Albu Michael L. Compositions and methods for paint overspray removal processes
EP1443905A4 (en) * 2001-10-03 2010-06-23 Univ Johns Hopkins COMPOSITIONS FOR ORAL GENE THERAPY AND METHOD OF USE THEREOF
PL370889A1 (en) * 2001-12-20 2005-05-30 Femmepharma, Inc. Vaginal delivery of drugs
WO2003059288A2 (en) * 2002-01-09 2003-07-24 Enzrel, Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
US20030176310A1 (en) * 2002-03-15 2003-09-18 Huang Robert Y.M. Chitosan/anionic surfactant complex membrane
ES2197836B1 (es) * 2002-06-28 2005-05-01 Consejo Sup. Investig. Cientificas Procedimiento para la preparacion de nano-emulsiones de tipo agua en aceite (w/o) por metodos de emulsificacion de condensacion.
US6780896B2 (en) * 2002-12-20 2004-08-24 Kimberly-Clark Worldwide, Inc. Stabilized photoinitiators and applications thereof
US8409618B2 (en) 2002-12-20 2013-04-02 Kimberly-Clark Worldwide, Inc. Odor-reducing quinone compounds
US7666410B2 (en) 2002-12-20 2010-02-23 Kimberly-Clark Worldwide, Inc. Delivery system for functional compounds
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
EP1578421A4 (en) * 2003-01-02 2009-04-22 Femmepharma Holding Co Inc PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF DISEASES AND BREAST CONDITIONS
WO2005018773A1 (en) * 2003-08-20 2005-03-03 Merck Patent Gmbh Methods for extraction and concentration of hydrophilic compounds from hydrophobic liquid matrices
US7794737B2 (en) 2003-10-16 2010-09-14 Kimberly-Clark Worldwide, Inc. Odor absorbing extrudates
US7678367B2 (en) 2003-10-16 2010-03-16 Kimberly-Clark Worldwide, Inc. Method for reducing odor using metal-modified particles
US7879350B2 (en) 2003-10-16 2011-02-01 Kimberly-Clark Worldwide, Inc. Method for reducing odor using colloidal nanoparticles
US7837663B2 (en) 2003-10-16 2010-11-23 Kimberly-Clark Worldwide, Inc. Odor controlling article including a visual indicating device for monitoring odor absorption
US7488520B2 (en) 2003-10-16 2009-02-10 Kimberly-Clark Worldwide, Inc. High surface area material blends for odor reduction, articles utilizing such blends and methods of using same
US7413550B2 (en) 2003-10-16 2008-08-19 Kimberly-Clark Worldwide, Inc. Visual indicating device for bad breath
US7754197B2 (en) 2003-10-16 2010-07-13 Kimberly-Clark Worldwide, Inc. Method for reducing odor using coordinated polydentate compounds
KR20060097020A (ko) * 2003-10-31 2006-09-13 테바 파마슈티컬 인더스트리즈 리미티드 약물 전달용 나노입자
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
US7846201B2 (en) * 2004-02-20 2010-12-07 The Children's Hospital Of Philadelphia Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
US8562505B2 (en) * 2004-02-20 2013-10-22 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US9028829B2 (en) * 2004-02-20 2015-05-12 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US20060003956A1 (en) * 2004-03-03 2006-01-05 Casadome David O Materials and methods for the derepression of the E-cadherin promoter
WO2005087221A1 (en) * 2004-03-15 2005-09-22 Christine Allen Biodegradable biocompatible implant and method of manufacturing same
CN1311867C (zh) * 2004-09-27 2007-04-25 侯新朴 一种用于鼻腔给药的神经生长因子制剂
ES2259914B1 (es) * 2005-03-14 2007-06-16 Advanced In Vitro Cell Technologies, S.L. Nanoparticulas de quitosano y polietilenglicol como sistema de administracion de moleculas biologicamente activas.
ATE515260T1 (de) * 2006-03-13 2011-07-15 Advanced In Vitro Cell Technologies S L Stabile nanokapselsysteme für die verabreichung von wirkstoffen
US7977103B2 (en) 2006-04-20 2011-07-12 Kimberly-Clark Worldwide, Inc. Method for detecting the onset of ovulation
US20080153789A1 (en) * 2006-12-26 2008-06-26 Femmepharma Holding Company, Inc. Topical administration of danazol
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
EP2162120B1 (en) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
EP2231169B1 (en) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
US8778400B2 (en) * 2008-04-21 2014-07-15 University Of South Australia Nanoparticle-stabilized capsule formulation for treatment of inflammation
US9207242B2 (en) 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
EP2266546A1 (en) 2009-06-08 2010-12-29 Advancell Advanced in Vitro Cell Technologies,S.A. Process for the preparation of colloidal systems for the delivery of active compounds
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
CA2767342C (en) 2009-07-09 2018-05-01 Oshadi Drug Administration Ltd. Matrix carrier compositions, methods and uses
EP2361509A1 (en) 2010-02-15 2011-08-31 Nestec S.A. Liquid-filled protein-phosphatidic acid capsule dispersions
EP2364600A1 (en) 2010-02-18 2011-09-14 Nestec S.A. Liquid-filled chitosan-anionic liposoluble capsule dispsersions
BRPI1002601E2 (pt) * 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos
US9326980B2 (en) * 2013-07-21 2016-05-03 Kimia Zist Parsian (Kzp) Method and system for synthesizing nanocarrier based long acting drug delivery system for buprenorphine
US9351932B2 (en) * 2014-07-21 2016-05-31 Kimia Zist Parsian (Kzp) Method and system for synthesizing nanocarrier based long acting drug delivery system for methadone
PL229276B1 (pl) 2015-07-17 2018-06-29 Univ Jagiellonski Nanokapsuła do przenoszenia związku lipofilowego i sposób jej wytwarzania
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
US20200129575A1 (en) 2017-02-09 2020-04-30 Universidade De Santiago De Compostela Purified pollen particles and use thereof for administering nanosystems
US11883401B2 (en) 2019-01-08 2024-01-30 Duke University Compositions for the treatment of pathogenic- and/or chemical-induced lung injury and for the treatment of cancer and methods of using same
CN113677706A (zh) 2019-01-21 2021-11-19 新加坡保健服务私人有限公司 肝毒性的治疗
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
CA3146344A1 (en) 2019-05-03 2020-11-12 Singapore Health Services Pte. Ltd. Treatment and prevention of metabolic diseases
GB201906291D0 (en) 2019-05-03 2019-06-19 Singapore Health Serv Pte Ltd Treatment and prevention of metabolic diseases
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
EP4376948A1 (en) 2021-07-26 2024-06-05 Boehringer Ingelheim International GmbH Treatment and prevention of alcoholic liver disease
WO2023111196A1 (en) 2021-12-16 2023-06-22 Singapore Health Services Pte. Ltd. Treatment and prevention of glomerular disease
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
IL101241A (en) * 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier

Also Published As

Publication number Publication date
DE69634927T2 (de) 2008-05-15
ATE330636T1 (de) 2006-07-15
ES2093562A1 (es) 1996-12-16
CA2195881A1 (en) 1996-11-28
ES2093562B1 (es) 1997-07-01
US5843509A (en) 1998-12-01
DE69634927D1 (de) 2005-08-18
EP0771566A1 (en) 1997-05-07
EP0771566B1 (en) 2006-06-21
CA2195881C (en) 2006-09-12
WO1996037232A1 (es) 1996-11-28
PT771566E (pt) 2006-08-31

Similar Documents

Publication Publication Date Title
DK0771566T3 (da) Stabilisering af kolloidale systemer ved dannelsen af ioniske lipidpolysaccharidkomplekser
Zimmer et al. Evaluation of pilocarpine-loaded albumin particles as controlled drug delivery systems for the eye. II. Co-administration with bioadhesive and viscous polymers
US5989535A (en) Polymeric bioadhesive emulsions and suspensions and methods of treatment
JP3323499B2 (ja) 正電荷粒子の油／水エマルジョン
Badawi et al. Chitosan based nanocarriers for indomethacin ocular delivery
Gurny et al. Ocular therapy with nanoparticulate systems for controlled drug delivery
AU692460B2 (en) Bioadhesive emulsion preparations for enhanced drug delivery
EP0995435B1 (en) Aqueous suspension preparations with excellent redispersibility
US5993831A (en) Composition providing a lasting cosmetic and/or pharmaceutical treatment of the upper epidermal layers by topical application on the skin
Davies et al. Evaluation of mucoadhesive polymers in ocular drug delivery. II. Polymer-coated vesicles
JP2969584B2 (ja) 眼の治療用組成物
AU673023B2 (en) Cosmetic delivery system for salicylic acid and process for preparation of the same
US5660853A (en) Process for manufacturing a cosmetics composition for application to hair, composition obtained by this process and process for cosmetic treatment using the said composition
JP3624418B2 (ja) リポソーム点眼液
EP0609963B1 (en) Topical compositions comprising benzimidazoles and benzotriazoles
Diepold et al. Distribution of poly-hexyl-2-cyano-[3-14C] acrylate nanoparticles in healthy and chronically inflamed rabbit eyes
CA2233501C (en) Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
WO2000009096B1 (en) Injectable formulations of nanoparticulate naproxen
WO1993000076A1 (en) Carrier systems for drugs
EP0463065B1 (en) Novel antiperspirant adduct compositions and process for making same
WO1998011874A1 (en) Pharmaceutical composition forming a gel
JPS60204708A (ja) 化粧料用保湿剤
WO1992003123A1 (en) Liposome alternative bilayer formulations
JPH08510731A (ja) 治療使用のためのその場で生成するゲル
Bhadra et al. Multicomposite ultrathin capsules for sustained ocular delivery of ciprofloxacin hydrochloride